|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Vir Biotechnology, Inc. (VIR) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Fri 2/14
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
127,390,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0 - $0 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Vir Biotechnology is a commercial-stage immunology company focused on combining immunologic insights with technologies to treat and prevent serious infectious diseases. Co.'s existing pipeline consists of sotrovimab and other product candidates targeting COVID-19, hepatitis B virus, influenza A virus, and human immunodeficiency virus. Co. has collaborate with Glaxo Wellcome UK Limited and GlaxoSmithKline Biologicals S.A. to focus on treating and preventing severe acute respiratory syndrome coronavirus 2 (the virus that causes COVID-19 illness). Co. is developing differentiated monoclonal antibodies, like sotrovimab and VIR-7832, as well as vaccines and small molecules.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
82,912 |
160,819 |
181,232 |
352,631 |
| Total Sell Value |
$490,388 |
$1,261,638 |
$1,434,081 |
$3,149,791 |
| Total People Sold |
2 |
7 |
7 |
10 |
| Total Sell Transactions |
2 |
11 |
16 |
27 |
| End Date |
2025-04-03 |
2024-12-31 |
2024-07-02 |
2023-07-03 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Sato Vicki L |
Director |
– • – |
2025-07-01 |
4 |
AS |
$5.10 |
$112,207 |
D/D |
(22,000) |
1,298,391 |
|
- |
|
| More Robert J |
Director |
– • – |
2025-06-09 |
4 |
A |
$0.00 |
$0 |
I/I |
14,027 |
509,917 |
|
- |
|
| More Robert J |
Director |
– • – |
2025-06-09 |
4 |
D |
$0.00 |
$0 |
D/D |
(14,027) |
40,656 |
|
- |
|
| Bischofberger Norbert W |
Director |
– • – |
2025-06-06 |
4 |
A |
$0.00 |
$0 |
I/I |
10,667 |
10,667 |
|
- |
|
| Bischofberger Norbert W |
Director |
– • – |
2025-06-06 |
4 |
D |
$0.00 |
$0 |
D/D |
(10,667) |
13,333 |
|
- |
|
| Napolitano Janet |
Director |
– • – |
2025-06-02 |
4 |
AS |
$5.05 |
$16,149 |
D/D |
(3,200) |
16,416 |
|
- |
|
| Hatfield Jeffrey S. |
Director |
– • – |
2025-05-30 |
4 |
A |
$0.00 |
$0 |
D/D |
8,000 |
31,806 |
|
- |
|
| Napolitano Janet |
Director |
– • – |
2025-05-30 |
4 |
A |
$0.00 |
$0 |
D/D |
8,000 |
19,616 |
|
- |
|
| Ramasastry Saira |
Director |
– • – |
2025-05-30 |
4 |
A |
$0.00 |
$0 |
D/D |
8,000 |
22,619 |
|
- |
|
| Bischofberger Norbert W |
Director |
– • – |
2025-05-30 |
4 |
A |
$0.00 |
$0 |
D/D |
8,000 |
24,000 |
|
- |
|
| Sigal Charles Elliott |
Director |
– • – |
2025-05-30 |
4 |
A |
$0.00 |
$0 |
D/D |
8,000 |
31,806 |
|
- |
|
| Farid Ramy |
Director |
– • – |
2025-05-30 |
4 |
A |
$0.00 |
$0 |
D/D |
8,000 |
24,000 |
|
- |
|
| Sato Vicki L |
Director |
– • – |
2025-05-30 |
4 |
A |
$0.00 |
$0 |
D/D |
8,000 |
1,320,391 |
|
- |
|
| More Robert J |
Director |
– • – |
2025-05-30 |
4 |
A |
$0.00 |
$0 |
D/D |
8,000 |
54,683 |
|
- |
|
| De Backer Marianne |
Chief Executive Officer |
• • – |
2025-04-03 |
4 |
S |
$5.95 |
$474,239 |
D/D |
(79,712) |
769,505 |
|
- |
|
| De Verneuil Vanina |
EVP and General Counsel |
• – – |
2025-02-26 |
4 |
AS |
$9.14 |
$67,402 |
D/D |
(7,373) |
79,460 |
|
- |
|
| De Verneuil Vanina |
EVP and General Counsel |
• – – |
2025-02-24 |
4 |
S |
$9.45 |
$48,590 |
D/D |
(5,140) |
86,833 |
|
- |
|
| Hanly Ann M. |
EVP & Chief Technology Officer |
• – – |
2025-02-24 |
4 |
S |
$9.45 |
$133,936 |
D/D |
(14,168) |
117,901 |
|
- |
|
| De Backer Marianne |
Chief Executive Officer |
• • – |
2025-02-24 |
4 |
S |
$9.45 |
$152,408 |
D/D |
(16,122) |
849,217 |
|
- |
|
| Sabatini Brent |
SVP, Chief Accounting Officer |
• – – |
2025-02-24 |
4 |
S |
$9.45 |
$14,766 |
D/D |
(1,562) |
46,627 |
|
- |
|
| Scangos George A |
Director |
– • – |
2025-02-24 |
4 |
S |
$9.45 |
$95,063 |
D/D |
(10,056) |
698,239 |
|
- |
|
| De Verneuil Vanina |
EVP and General Counsel |
• – – |
2025-02-22 |
4 |
A |
$0.00 |
$0 |
D/D |
35,000 |
91,973 |
|
- |
|
| De Backer Marianne |
Chief Executive Officer |
• • – |
2025-02-22 |
4 |
A |
$0.00 |
$0 |
D/D |
240,000 |
865,339 |
|
- |
|
| Obyrne Jason |
EVP & Chief Financial Officer |
• – – |
2025-02-22 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
115,000 |
|
- |
|
| Eisner Mark |
EVP and Chief Medical Officer |
• – – |
2025-02-22 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
115,000 |
|
- |
|
628 Records found
|
|
Page 1 of 26 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
